RESUMO
In this work, a ternary TiO2/Graphene oxide/Polyaniline (TiO2/GO/PANI) nanocomposite was synthesized by in situ oxidation and use as a filler on epoxy resin (TiO2/GO/PANI/EP), a bifunctional in situ protective coating has been developed and reinforced the Q235 carbon steel protection against corrosion. The structure and optical properties of the obtained composites are characterized by XRD, FTIR, and UV-vis. Compared to bare TiO2 and bare Q235, the TiO2/GO/PANI/EP coating exhibited prominent photoelectrochemical properties, such as the photocurrent density increased 0.06 A/cm2 and the corrosion potential shifted from -651 mV to -851 mV, respectively. The results show that the TiO2/GO/PANI nanocomposite has an extended light absorption range and the effective separation of electron-hole pairs improves the photoelectrochemical performance, and also provides cathodic protection to Q235 steel under dark conditions. The TiO2/GO/PANI/EP coating can isolate the Q235 steel from the external corrosive environment, and may generally be regarded a useful protective barrier coating to metallic materials. When the TiO2/GO/PANI composite is dispersed in the EP, the compactness of the coating is improved and the protective barrier effect is enhanced.
RESUMO
BACKGROUND: Clinical trials are at the cornerstone of evidence-based stem cell therapies, but the quality assessment for designing and conduct these sometimes-complex studies are scarce of evidence. This study is aimed at developing a handy quality assessment tool for stem cell clinical trials, enhancing capacity of the self-regulate overall quality, and participating protection. METHODS: The framework of quality assessment tool was based on the PQRS (progress-quality-regulation-scientific) quality assessment tool, and detailed quality indicators were developed by leader group discussion, expert consulting, and literature review. Stem cell clinical trials were retrieved from the International Clinical Trials Registry Platform, and corresponding quality indicators were assessed and extracted. The validity and feasibility of conceptual quality assessment tool were further evaluated by using structural equation modeling. RESULTS: The quality assessment tool for stem cell clinical trials contains four critical quality attributes, including participant protection, scientific value, quality control, and stem cell products, and 9 observed quality indicators. From 11 primary clinical trial registries in the International Clinical Trials Registry Platform, 9410 stem cell trial registrations were identified, and 1036 studies were eligible for publications and protocols screening. After reviewed full text, 37 studies were included in the validity and feasibility evaluation: 32 studies were completed, and 3 studies terminated early. Most of the studies (83.79%) were in the early phase, and 63.16% of the studies were investigator-initiated trial. To further tested for validity, the critical quality attributes and quality indicators (QIs) between expertise further validated by the SEM method, which showed a good fit for the model (chi - square = 26.008; P = 0.353; TLI = 0.967; CFI = 0.978; RMSEA = 0.048). Compared with exploratory trials, evaluating using the quality assessment tool, confirmatory trials performed similarly in participant protection, scientific value, and quality control, but lower in stem cell products. CONCLUSIONS: The results of critical quality attributes and quality indicators between expertise and confirmatory validation analysis are basically consistent, indicating the feasibility and validity of applying this quality assessment tool for overall quality evaluation of stem cell trials.
